Abstract | INTRODUCTION: 'Female sexual dysfunction' (FSD) is an umbrella term comprising a range of common disorders, including hypoactive sexual desire, reduced subjective and/or physical genital arousal (poor sensation, vasocongestion, lubrication), sexual pain and inability to achieve orgasm/satisfaction, which are multidimensional by nature and often coexisting. Psychological and contextual factors have a significant influence on organic components of sexual response and behavior and a tailored medical approach to sexual symptoms is inevitably limited. AREAS COVERED: EXPERT OPINION: We are still waiting for an approved pharmacotherapy for FSD. This is not the result of gender inequality in sexual medicine, but it reflects the need of balancing benefits and risks in order to provide effective and safe treatments to women of any age.
|
Authors | Rossella E Nappi, Laura Cucinella |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 16
Issue 6
Pg. 875-87
(Apr 2015)
ISSN: 1744-7666 [Electronic] England |
PMID | 25732267
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Estrogens
- Norpregnenes
- Piperazines
- Purines
- Selective Estrogen Receptor Modulators
- Sulfonamides
- Tamoxifen
- Testosterone
- Ospemifene
- Sildenafil Citrate
- tibolone
- Buspirone
|
Topics |
- Buspirone
(therapeutic use)
- Clinical Trials, Phase III as Topic
- Estrogens
(therapeutic use)
- Female
- Humans
- Menopause
- Norpregnenes
(therapeutic use)
- Piperazines
(therapeutic use)
- Purines
(therapeutic use)
- Selective Estrogen Receptor Modulators
(therapeutic use)
- Sexual Behavior
- Sexual Dysfunction, Physiological
(drug therapy, physiopathology, psychology)
- Sexual Dysfunctions, Psychological
(drug therapy, physiopathology, psychology)
- Sildenafil Citrate
- Sulfonamides
(therapeutic use)
- Tamoxifen
(analogs & derivatives, therapeutic use)
- Testosterone
(therapeutic use)
|